What is the recommended treatment for mycoplasma genitalium?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mycoplasma Genitalium Treatment

The first-line treatment for Mycoplasma genitalium is azithromycin 1g orally in a single dose, as it has better efficacy (85-95% cure rate in macrolide-susceptible infections) compared to doxycycline (30-40% cure rate). 1, 2

Diagnostic Considerations

  • Testing for M. genitalium is recommended in patients with urethritis, cervicitis, or related genital tract infections 1
  • Co-testing for gonorrhea and chlamydia should be performed as co-infections are common 1
  • Diagnosis requires nucleic acid amplification testing (NAAT), ideally followed by testing for macrolide resistance if available 2

Treatment Algorithm

First-Line Treatment

  • Azithromycin 1g orally in a single dose 1
  • Extended azithromycin regimen (500mg on day one, then 250mg on days 2-5) appears to have higher cure rates and may be preferred to reduce risk of resistance development 3, 2

Alternative First-Line Options

  • Doxycycline 100mg orally twice daily for 7 days (less effective but does not increase resistance) 1, 2
  • Other alternatives include erythromycin base 500mg orally four times daily for 7 days, erythromycin ethylsuccinate 800mg orally four times daily for 7 days, levofloxacin 500mg orally once daily for 7 days, or ofloxacin 300mg orally twice daily for 7 days 1

Second-Line Treatment (for macrolide-resistant infections)

  • Moxifloxacin 400mg once daily for 7-14 days 4, 2, 5
  • Cure rates with moxifloxacin have decreased from 100% to 89% since 2010 due to emerging resistance 6

Third-Line Treatment Options (for persistent infections)

  • Doxycycline or minocycline 100mg twice daily for 14 days (40-70% cure rate) 4, 2
  • Pristinamycin 1g four times daily for 10 days (approximately 75% cure rate) 4, 2

Treatment Considerations and Caveats

Resistance Concerns

  • Macrolide resistance in M. genitalium exceeds 50% in many regions 5
  • Single-dose azithromycin (1g) may increase the development of macrolide resistance and should be used with caution 4, 7
  • Resistance-guided therapy (testing for macrolide resistance mutations before treatment) is increasingly recommended to optimize outcomes 2, 5
  • Pre-treatment with doxycycline may decrease organism load and reduce risk of macrolide resistance selection 2

Special Situations

  • For complicated M. genitalium infections (PID, epididymitis): moxifloxacin 400mg once daily for 14 days 3, 2
  • Multidrug-resistant infections (both macrolide and fluoroquinolone resistance) are emerging and may require pristinamycin or other specialized treatments 7

Follow-Up Recommendations

  • Patients should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of a multi-day regimen 1
  • Sexual partners should be evaluated and treated to prevent reinfection 1, 4
  • Patients should return for evaluation if symptoms persist or recur after treatment 1, 4
  • Test of cure is not routinely recommended if symptoms resolve, but may be considered 3-6 months after treatment for resistant infections 1, 4

References

Guideline

Treatment for Mycoplasma Genitalium

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

2021 European guideline on the management of Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2022

Research

2016 European guideline on Mycoplasma genitalium infections.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2016

Guideline

Treatment of Tetracycline-Resistant Mycoplasma Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.